Prabhudas Lilladher's research report on P.I. Industries
PI reported better than expected results driven by strong demand for key commercialised molecules and Isagro’s performance. Prudent raw material management, traction for branded portfolio, higher utilisation rates and better contribution from ISAGRO drove better than expected EBITDA growth of 34% to Rs 2.8 bn (PLe Rs 2.4 bn). We believe ramp up of 4 recently commercialised molecules and pipeline of +40 products (5-6 molecules in FY22, 12-15 molecules in the next 2 years) will drive growth in coming years, along with foray in pharma intermediates and inorganic opportunities. Management is evaluating few options very actively for inorganic growth (one in additives industry) and their endeavour is to generate better returns over a period of time than the current business. We are also keenly observing PI’s progress into the Pharma and other adjacent chemistry value chain, as it is likely to be a key determinant for further re-rating.
Outlook
We have increased our topline/ EBITDA/ APAT estimates by 3%/2%/2% for FY21, 4%/4%/5% for FY22 and 4%/4%/5% for FY23. Maintain HOLD with revised TP of Rs 2119 (Previous 2026) based on 30x FY23 EPS of Rs 70.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.